These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 1370650)

  • 1. Synthesis and evaluation of fluoromycin: a novel fluorescence-labeled derivative of talisomycin S10b.
    Mistry JS; Jani JP; Morris G; Mujumdar RB; Reynolds IJ; Sebti SM; Lazo JS
    Cancer Res; 1992 Feb; 52(3):709-18. PubMed ID: 1370650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics of bleomycin-resistant phenotypes of human cell sublines and circumvention of bleomycin resistance by liblomycin.
    Lazo JS; Braun ID; Labaree DC; Schisselbauer JC; Meandzija B; Newman RA; Kennedy KA
    Cancer Res; 1989 Jan; 49(1):185-90. PubMed ID: 2461797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liblomycin-mediated DNA cleavage in human head and neck squamous carcinoma cells and purified DNA.
    Wassermann K; Zwelling LA; Lown JW; Hartley JA; Nishikawa K; Lin JR; Newman RA
    Cancer Res; 1990 Mar; 50(6):1732-7. PubMed ID: 1689610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lidocaine potentiation of bleomycin A2 cytotoxicity and DNA strand breakage in L1210 and human A-253 cells.
    Lazo JS; Braun ID; Meandzija B; Kennedy KA; Pham ET; Smaldone LF
    Cancer Res; 1985 May; 45(5):2103-9. PubMed ID: 2580616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cysteine proteinase inhibitors and bleomycin-sensitive and -resistant cells.
    Morris G; Mistry JS; Jani JP; Sebti SM; Lazo JS
    Biochem Pharmacol; 1991 Jun; 41(11):1559-66. PubMed ID: 1710457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural basis for the sequence selectivity of DNA cleavage by bleomycins.
    Mistry JS; Koepsel RR; Lazo JS
    Biochem Biophys Res Commun; 1993 Mar; 191(2):420-6. PubMed ID: 7681666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Sensitivity to bleomycin of human cultured tumor cells and analysis of related factors].
    Urade M; Sugi M; Shirasuna K; Sugiyama M; Miyazaki T
    Gan To Kagaku Ryoho; 1983 Nov; 10(11):2382-8. PubMed ID: 6195972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tallysomycin S10b: experimental antitumor activity and toxicity.
    Schurig JE; Rose WC; Hirth RS; Schlein A; Huftalen JB; Florczyk AP; Bradner WT
    Cancer Chemother Pharmacol; 1984; 13(3):164-70. PubMed ID: 6207948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutralization of bleomycin hydrolase by an epitope-specific antibody.
    Morris G; Mistry JS; Jani JP; Mignano JE; Sebti SM; Lazo JS
    Mol Pharmacol; 1992 Jul; 42(1):57-62. PubMed ID: 1378925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased glutathione level is not involved in enhanced bleomycin sensitivity in cisplatin-resistant 2780CP cells.
    Tanaka T; Kurokawa H; Matsuno K; Matsumoto S; Hayashida Y
    Anticancer Res; 2008; 28(5A):2663-8. PubMed ID: 19035292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro selection and characterization of a bleomycin-resistant subline of B16 melanoma.
    Zuckerman JE; Raffin TA; Brown JM; Newman RA; Etiz BB; Sikic BI
    Cancer Res; 1986 Apr; 46(4 Pt 1):1748-53. PubMed ID: 2418953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines.
    Ohe Y; Nakagawa K; Fujiwara Y; Sasaki Y; Minato K; Bungo M; Niimi S; Horichi N; Fukuda M; Saijo N
    Cancer Res; 1989 Aug; 49(15):4098-102. PubMed ID: 2472873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of bleomycin, tallysomycin S10b, and liblomycin against fresh human tumor cells.
    Tueni EA; Newman RA; Baker FL; Ajani JA; Fan D; Spitzer G
    Cancer Res; 1989 Mar; 49(5):1099-102. PubMed ID: 2465080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological and toxicological aspects of new imidazoacridinone antitumor agents.
    Berger B; Marquardt H; Westendorf J
    Cancer Res; 1996 May; 56(9):2094-104. PubMed ID: 8616856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Substrate specificity of bleomycin hydrolase.
    Sebti SM; DeLeon JC; Ma LT; Hecht SM; Lazo JS
    Biochem Pharmacol; 1989 Jan; 38(1):141-7. PubMed ID: 2462878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of DNA damage and single- and double-strand breakage activities on PM-2 DNA by talisomycin and bleomycin analogs.
    Mirabelli CK; Huang CH; Crooke ST
    Cancer Res; 1980 Nov; 40(11):4173-7. PubMed ID: 6162546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic inactivation: a mechanism of human tumor resistance to bleomycin.
    Sebti SM; Jani JP; Mistry JS; Gorelik E; Lazo JS
    Cancer Res; 1991 Jan; 51(1):227-32. PubMed ID: 1703034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of hyperthermia with bleomycin and liblomycin: effects on CHO cells in vitro.
    Dogramatzis D; Nishikawa K; Newman RA
    Anticancer Res; 1991; 11(3):1359-64. PubMed ID: 1716087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bleomycin induced changes in growth and cell kinetics of a heterotransplanted squamous cell carcinoma of the head and neck.
    Wennerberg J
    Anticancer Res; 1984; 4(6):419-23. PubMed ID: 6083742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bleomycin hydrolase activity and cytotoxicity in human tumors.
    Lazo JS; Boland CJ; Schwartz PE
    Cancer Res; 1982 Oct; 42(10):4026-31. PubMed ID: 6179595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.